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Abstract
Reliable determination of Ki67 labeling index (Ki67-LI) on core needle biopsy (CNB) is essential for determining breast cancer
molecular subtype for therapy planning. However, studies on agreement between molecular subtype and Ki67-LI between CNB
and surgical resection (SR) specimens are conflicting. The present study analyzed the influence of clinicopathological and
sampling-associated factors on agreement. Molecular subtype was determined visually by Ki67-LI in 484 pairs of CNB and
SR specimens of invasive estrogen receptor (ER)–positive, human epidermal growth factor (HER2)–negative breast cancer.
Luminal B disease was defined by Ki67-LI > 20% in SR. Correlation of molecular subtype agreement with age, menopausal
status, CNB method, Breast Imaging Reporting and Data System imaging category, time between biopsies, type of surgery, and
pathological tumor parameters was analyzed. Recurrence-free survival (RFS) and overall survival (OS) were analyzed using the
Kaplan–Meier method. CNB had a sensitivity of 77.95% and a specificity of 80.97% for identifying luminal B tumors in CNB,
compared with the final molecular subtype determination after surgery. The correlation of Ki67-LI between CNB and SR was
moderate (ROC-AUC 0.8333). Specificity and sensitivity for CNB to correctly define molecular subtype of tumors according to
SR were significantly associated with tumor grade, immunohistochemical progesterone receptor (PR) and p53 expression
(p < 0.05). Agreement of molecular subtype did not significantly impact RFS and OS (p = 0.22 for both). The identified factors
likely mirror intratumoral heterogeneity that might compromise obtaining a representative CNB. Our results challenge the
robustness of a single CNB-driven measurement of Ki67-LI to identify luminal B breast cancer of low (G1) or intermediate
(G2) grade.
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Introduction
Reliable determination of molecular subtype is indispens-
able for prognostication and treatment decision in breast
cancer (BC) [1, 2]. Especially in estrogen receptor (ER)–
positive and human epidermal growth factor 2 (HER2)–
negative luminal BC, assessment of molecular subtype is
of critical prognostic importance [3–9]. Current St. Gallen
guidelines confirm the role of the proliferation marker
Ki67 labeling index (Ki67-LI) in discriminating good
prognosis “luminal A” (LumA) from “luminal B”
(LumB) disease with less favorable prognosis [2]. In the
absence of molecular assays, Ki67-LI still remains a main
factor governing molecular subtype determination and
(neo-)adjuvant treatment choice in early luminal-type BC
[1, 10–14]. However, reproducible and clinically valid
Ki67-LI determination in core needle biopsy (CNB) might
be biased by technical difficulties, assessment methods, or
intratumoral heterogeneity. Exact measures of standardi-
zation such as a cutoff value or compensating for
intratumoral heterogeneity remain elusive. Although digi-
tal image analysis seems a promising tool to facilitate
robust and reliable determination of Ki67-LI, additional
challenges still remain to be addressed [15, 16]. At pres-
ent, no universal Ki67-LI cutoff levels to define molecular
subtype in luminal BC are specified, and discrepancies
regarding implications on clinical decisions persist [1,
17–19]. Whereas cutoff values can be statistically validat-
ed, the influence of intratumoral heterogeneity on the re-
liability of Ki67-LI in CNB remains to be resolved.
Recommendations to standardize Ki67-LI assessment
recognized the need for further studies to evaluate com-
parability of Ki67-LI between CNB and whole tumor
slides of surgical resection (SR) specimens [17]. We
therefore evaluated the reliability of Ki67-LI to define
molecular subtype by analyzing the concordance between
CNB and SR specimens in 484 early untreated luminal-
type BC patients. We investigated clinicopathological fac-
tors and possible sampling-associated confounders, such
as CNB method and time between CNB and surgery that
might impact the reliability of molecular subtype/Ki67-LI
determination in CNB. Our results might help to improve
the interpretation of CNB-derived measurements as prog-
nostic indicators and outcome predictors in luminal BC.
The identification of factors that predict discrepancies be-
tween CNB and SR could aid the targeted implementation
of molecular assays in luminal BC cases where reliable
molecular subtype determination and neoadjuvant therapy
indication require additional analyses.
Patients and methods
Patients
Patients (n = 484) with ER+/HER2− invasive BC at the
Medical University of Vienna (MUW) were included in this
retrospective analysis. Study procedures were approved by the
Institutional Review Board of the MUW (1245/2017).
Patients with primary operable luminal BC stages I–III who
received diagnostic CNB and curative surgery without neoad-
juvant therapy between 2010 and 2012 were eligible to par-
ticipate. Age, menopausal status, type of surgery (breast con-
serving vs. mastectomy), and previous BC history were re-
corded for each patient. Clinical and pathological patient char-
acteristics are described in Table 1. Follow-up data was avail-
able for 390 (80.6%) patients. At a median follow-up of
62.6 months (ranged 1–105 months), 63 (16.2%) patients
had relapsed and 63 patients (16.2%) had died.
Radiology
All patients underwent pre-operative either stereotactic
vacuum-assisted (9G), ultrasound core needle (14G), or mag-
netic resonance imaging (MRI) vacuum-assisted (9G) guided
breast biopsy according to the European Society of Breast
Imaging (EUSOBI) guidelines [20]. In some patients, CNB
was performed under no image guidance (palpation).
Documented parameters included Breast Imaging Reporting
and Data System (BI-RADS) assessment category of image-
detected lesions, CNBmethod, and surgery time interval (STI)
between CNB and surgery (Table 1).
Pathology and immunohistochemistry
Workup was carried out according to the EU guidelines [21,
22] and theWHO classification [23]. Histopathological tumor
grade (G) [24, 25], tumor size (pT), multifocality, lymph node
(pN) status, and presence of peritumoral lymphovascular in-
vasion (LVI) were determined by two experienced patholo-
gists (ML, ZBH). All cases were reviewed together; discrep-
ant cases were discussed to reach consensus. All grading pa-
rameters (tubuloglandular differentiation, nuclear
pleomorphy, and mitotic count) were recorded separately for
CNB and SR, whereas measurements in SR were defined as
gold standard.
Assessment of ER, progesterone receptor (PR), HER2,
Ki67-LI, and p53 was performed using Ventana BenchMark
Ultra (Ventana, Tucson, AR, USA) according to the ASCO/
USCAP guidelines [26, 27]. Ki67-LI was determined as
546 Virchows Arch (2020) 477:545–555
described previously [28]. The entire tumor area was evaluat-
ed by estimation, yielding an average Ki67-LI score. LumA
molecular subtype was defined by a Ki67-LI of < 20%. To
enable comparability, % scores of ER, PR, Ki67, and p53
were normalized to ten-percentile values. Accordingly, cases
with Ki67-LI values between 10 and 14% were regarded as
LumA disease, whereas the definition of luminal B breast
cancer included cases with values between 15 and 20%.
Statistical analyses
Continuous data are presented as median, minimum, and
maximum due to skew distributions. Categorical data
are presented as absolute frequencies and percentages.
Sensitivities to correctly predict LumB molecular sub-
type in SR and specificities to predict LumA molecular
subtype by CNB are given partly together with 95%
confidence intervals according to the method of
Wilson. To assess diagnostic ability of CNB to predict
SR over several CNB cut-points, a receiver operating
characteristic (ROC) curve and its area under the curve
are given.
Associations between two binary variables are tested
by chi-square test or Fisher’s exact test in case of small
cell numbers. To test ordinal variables between LumA
and LumB molecular subtype, a trend chi-square test
was used and an exact version was used in case of small
numbers.
Table 1 Patients’ characteristics:
data are presented as median
(minimum-maximum) or as ab-
solute frequencies (percentages)
Clinicopathological parameters N (%)
Age (years)
Median (min-max) 62.5 (29.8–92.7)
Menopausal status
Premenopausal/postmenopausal/unknown 93 (19.2%)/379 (78.3%)/12 (2.5%)
Breast cancer history
No previous BC/recurrent BC 432 (89.3%)/52 (10.8%)
CNB method
US-guided/stereotactic/MR-guided/palpatory 389 (80.4%)/21 (4.3%)/50 (10.3%)/24 (5.0%)
BI-RADS assessment category
IV/V/unknown 160 (33.1%)/258 (58.9%)/39 (8.1%)
Surgery time interval (STI, days)
Median (min-max) 25.0 (2–105)
Type of surgery
Breast conserving surgery/mastectomy 362 (74.8%)/122 (25.2%)
Tumor type
NST/lobular/mixed/other 394 (81.4%)/70 (14.5%)/4 (0.8%)/16 (3.3%)
Grade
G1/G2/G3/GX CNB: 142 (29.3%)/247 (51.1%)/94 (19.4%)/1 (0.2%)
SR: 117 (24.2%)/253 (52.3%)/114 (23.6%)/---
Molecular subtype
LumA/LumB CNB: 207 (42.8%)/277 (57.2%)
SR: 195 (40.3%)/289 (59.7%)
In situ (DCIS) component in CNB
Yes/no 212 (43.8%)/272 (56.2%)
Tumor size
pT1/pT2/pT3/pT4 338 (69.8%)/128 (26.4%)/14 (2.9%)/4 (0.8%)
Focality
Unifocal tumor/multifocal tumor/unknown 364 (75.2%)/119 (24.6%)/1(0.2%)
Lymph node status
pN0/pN1a/pN2a/pN3a/pNx 325 (67.1%)/100 (20.7%)/25 (5.2%)/18 (3.7%)/16 (3.3%)
Lymphovascular invasion
Absent/mild/severe CNB: 465 (96.1%)/19 (3.9%)/---
SR: 340 (70.2%)/138 (28.5%)/6 (1.3%)
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Recurrence-free survival was defined as the interval be-
tween the CNB and the first evidence of relapse at any site
or incidence or contralateral breast cancer. Overall survival
was defined as the interval between CNB and death.
Survival rates were estimated with the use of the Kaplan–
Meier method.
All p values are two-sided and p ≤ 0.05 was considered sig-
nificant. Calculations were performed by the statistical software
SAS© (version 9.4, SAS Institute Inc., Cary, NC, USA).
Results
Concordance of Ki67-LI and molecular subtype
between CNB and SR
Median Ki67-LI was 21.4% and 21.7% for CNB and SR,
respectively. A substantial agreement of Ki67-LI between
CNB and SR specimens was observed. The ROC for molec-
ular subtype in CNB to correctly diagnose LumA in SR
(Ki67-LI < 20%) resulted in an area under the curve (AUC)
of 0.8333 (Fig. 1a), indicating moderate association. When
applying a cutoff point of CNB Ki67-LI < 20% for LumA
molecular subtype, 152 of 195 LumA cases were diagnosed
correctly (sensitivity 77.95%; 95% CI 71.62–83.20%) and 43
tumors were falsely classified as LumB by CNB. Two hun-
dred thirty-four out of 289 LumB cases were correctly classi-
fied as Ki67-LI ≥ 20% (specificity 80.97%; 95% CI 76.05–
85.08%), and 55 cases were falsely classified as LumA by
CNB (Fig. 1b).
Agreement of molecular subtype determination by Ki67-LI
was observed in 386 (79.8%) patients. In 98 (20.3%) patients,
Ki67-LI in CNB and SR were discordant. Examples are
shown in Fig. 2.
CNB-related factors influencing agreement
In our analysis, we identified tumor grade (including all sepa-
rate grading components), lower PR expression, higher p53
expression, and LVI as tumor-related factors in CNB that sig-
nificantly influenced agreement of molecular subtype. A depen-
dence between ER expression in CNB and Ki67-LI for LumA
and LumB tumors could not be demonstrated, mainly due to
small group sizes with ER < 80% in CNB (7 LumA tumors and
14 LumB tumors). Results are shown in detail in Table 2.
SR-related factors influencing agreement
In SR specimens, tumor grade (including all separate grading
components), tumor size (pT), multifocality, lymph node in-
volvement (pN), LVI, and performed mastectomy were iden-
tified as tumor-related factors that significantly influenced
agreement of molecular subtype. Results are shown in detail
in Table 3.
Prognostic significance of molecular subtype
agreement
Survival data was available for 390 patients, of whom 177
(30%) were correctly diagnosed with luminal A tumors and
Fig. 1 a Receiver operating characteristics (ROC) curve for luminal IST
by CNB. Numbers given are true positive rate and correspond to CNB
cutoff values of < 5, < 10, < 20, < 30, < 40, and < 50, respectively. b
Agreement of luminal IST determination in core needle biopsy (CNB)
and surgical resection (SR) specimens. Using a cutoff value of < 20% for
LumA IST, 386 cases (79.8%) were correctly classified in CNB; 98 cases
(20.5%) showed discordant IST
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199 (51%) were correctly diagnosed with luminal B disease in
CNB. In 43 patients (11.2%), a LumA tumor in CNB was
upgraded to LumB by SR and in 31 patients (7.9%), a
LumB tumor in CNB was downgraded to LumA by SR.
Kaplan–Meier analyses revealed no significant differences re-
garding RFS and OS (log-rank test, p = 0.22, respectively).
However, patients with correctly diagnosed LumB tumors
tended to have a worse RFS and OS, as shown in Fig. 3.
Discussion
The present study analyzed concordance of Ki67-LI between
corresponding CNB and SR in BC with respect to defining
molecular subtype. Our aim was to identify method- and
tumor-related factors that influence reliability of Ki67-LI/
molecular subtype determination in CNB. Although smaller
studies have previously been conducted [29–31], our study is
distinguished by the inclusion of patients with luminal BC
exclusively, as Ki67-LI has a therapeutic consequence only
in these patients [30]. Of particular importance is the reliable
identification of LumB disease in CNB, as in these patients,
neoadjuvant chemotherapy is often indicated.
In our study, 79.8% of tumors were reliably classified ac-
cording to molecular subtype, indicating a moderate agree-
ment. Discrepancies in Ki67-LI between CNB and SR sam-
ples have been reported, even when no neoadjuvant systemic
therapy was applied [32]. Sampling errors as well as
intratumoral heterogeneity leading to a non-representative
CNB have been discussed as potential confounding factors
[17]. The abundance of tumor cells in SR compared with
CNB can represent intratumoral heterogeneity to a higher
Fig. 2 Hematoxylin and eosin (HE) and Ki67-LI immunohistochemical
stainings showing breast cancer cases displaying concordant and discor-
dant luminal IST and Ki67-LI in CNB and SR, respectively (× 100 mag-
nification). a HE and respective Ki67-LI IHC slides of two patients with
concordant Ki67-LI when comparing CNB and SR. A1 Ki67-LI 60%
indicating LumB IST in both CNB and SR; A2 10% Ki67 indicating
LumA IST in both CNB and SR. b HE and respective Ki67 IHC slides
of two patients with discordant luminal ISTandKi67-LI when comparing
CNB and SR. B1 Ki67 10% (LumA) in CNB, 30% (LumB) in SR; B2
20% (LumB) Ki67-LI in CNB, 5% (LumA) in SR.
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degree. Therefore, the representativity of CNBmight be ques-
tionable [29, 33, 34]. Ki67-LI in SR was more accurately
mirrored by CNB than by tissue microarrays, without direct
influence of CNB size on reliability [29, 33–35]. Recent stud-
ies addressing intratumoral heterogeneity demonstrated that
inhomogeneous distribution of tumor proliferation within sin-
gle tumors exceeded Ki67-LI variation between individual
luminal-type tumors [36].
Further factors such as post-acquisition handling have been
considered to be of influence as well. A prolonged time span
between extraction and fixation leading to hypoxic tissue
damage and in succession to apoptosis of tumor cells and
degradation of the Ki67 nuclear protein might result in a lower
Ki67-LI in SR samples [29, 37].
We demonstrated that the CNB method did not significant-
ly influence reliability of molecular subtype determination,
whereas MRI-guided biopsies showed the lowest concor-
dance rates (data not shown). By evaluating the influence of
the time interval between CNB and surgery, we analyzed
whether wound healing processes after CNB impact local tu-
mor proliferation. Previous studies suggested that surgery
time interval might influence Ki67-LI change after CNB, lon-
ger STI leading to a higher increase in Ki67-LI [38]. In our
analysis, surgery time interval did not interfere with Ki67-LI
and molecular subtype concordance and reliability. However,
median surgery time interval differed significantly in the two
studies (4.5 days reported by Chen at al. vs. 25 days in this
study, respectively), which provides a possible explanation for
Table 2 Tumor-related factors in CNB influencing agreement of luminal IST
Intrinsic subtype (n) Specificity (%) * p value Intrinsic subtype (n) Sensitivity (%) ** p value
LumASR LumBSR
LumACNB LumBCNB LumACNB LumBCNB
Total 152 43 78.0 55 234 81.0
CNB-grade G1 85 12 87.6 0.0007 28 17 37.8 < 0.0001
G2 67 30 69.1 24 126 84
G3 0 1 0 3 90 96.8
Missing 1
SR-grade G1 78 11 - 0.0061 16 12 - < 0.0001
G2 73 32 35 113
G3 1 0 4 109
CNB-nuclear pleomorphy 1 39 3 92.9 0.0066 11 6 35.3 < 0.0001
2 108 37 74.5 43 164 79.2
3 5 3 62.5 1 64 98.5
CNB-mitotic count 1 143 29 83.1 0.0003 49 87 64.0 < 0.0001
2 8 11 42.1 4 56 93.3
3 1 1 50.0 1 87 98.9
Missing 0 2 0 1 4 80.0
CNB lymphovasc. invasion No 152 43 78.0 - 54 216 80.00 0.1390
Yes 0 0 - 1 18 94.74
CNB ER 10–30% 0 1 0 0.1027 0 1 100 0.3548
40–70% 4 2 66.7 1 12 92.3
80–100% 148 40 78.7 54 221 80.3
CNB PR neg. 22 7 75.9 0.7984 2 30 93.8 0.0006
10–30% 14 1 93.3 2 39 95.1
40–70% 37 12 75.5 16 65 80.2
80–100% 79 23 77.5 35 100 74.1
CNB p53 neg. 148 40 78.72 0.0868 51 172 77.13 0.0017
10–30% 4 2 66.67 4 37 90.24
40–60% 0 0 - 0 16 100
70–100% 0 1 0 0 9 100
* Specificity is the percentage of correctly diagnosed LumA patients by CNB
** Sensitivity is the percentage of correctly diagnosed LumB patients by CNB
Missing values were ignored in statistical tests
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this discrepancy: a transient rise in Ki67-LI caused by wound
healing processes is likely abated after a longer STI.
In our study, further clinicopathological factors, most im-
portantly G and size, PR and p53 expression influenced sen-
sitivity and specificity of molecular subtype determination.
These factors are likely indicators of intratumoral heterogene-
ity and might therefore predict reliability of molecular subtype
assessment in CNB. Previous analyses confirmed that adverse
clinicopathological factors such as high G, LVI, and high p53
expression were significantly associated with a high Shannon
index regarding copy number variation of oncogenes, impli-
cating these factors as indicators of intratumoral heterogeneity
[39].
ER-negative tumors display higher concordance rates be-
tween CNB and SR than ER-positive tumors [30]. In our
study, PR negativity was significantly associated with in-
creased concordance in luminal BC. Furthermore, inferior
agreement was found in G1 and G2 tumors compared with
G3 tumors. We also reported a lower Ki67-LI concordance
rate and lower luminal molecular subtype agreement in com-
parison with the distinction between luminal and non-luminal
subtype [30].
We now report that additional factors, such as multifocality,
PR, and p53 expression, also affect sensitivity of Ki67-LI
assessment. Considering these factors is likely to increase
the acuity of molecular subtype determination.
Table 3 Tumor-related factors in SR influencing agreement of luminal IST
Intrinsic subtype (n) p value Intrinsic subtype (n) p value
LumASR LumBSR
LumACNB LumBCNB LumACNB LumBCNB
Total 152 43 55 234
SR-grade G1 78 11 0.0061 16 12 < 0.0001
G2 73 32 35 113
G3 1 0 4 109
SR-glandular differentiation 1 39 7 0.2024 5 7 0.0009
2 43 12 21 53
3 70 24 29 173
Missing 0 0 - 0 1 -
SR-nuclear pleomorphy 1 34 4 0.0137 5 4 < 0.0001
2 103 30 36 102
3 15 9 14 127
Missing 0 0 - 0 1 -
SR-mitotic count 1 142 39 0.7627 36 91 < 0.0001
2 9 4 14 53
3 1 0 5 89
Missing 0 0 - 0 1 -
SR pT pT1 124 36 0.7466 37 141 0.3357
≥ pT2 28 7 18 93
SR lymphovascular invasion no 126 40 0.0993 38 136 0.0945
Yes—mild 26 3 17 92
Yes—
severe
0 0 - 0 6 -
Multifocality No 124 29 0.0465 45 166 0.1110
Yes 28 14 10 67
Missing 0 1 -
SR-pN Negative 114 36 0.4132 34 141 0.7858
pN1a 29 6 13 52
pN2a 2 0 4 19
pN3a 4 1 2 11
Missing 3 0 - 2 11 -
Breast conserving surgery Mastectomy 31 17 0.0101 9 65 0.0809
BCS 121 26 46 169
Missing values were ignored in statistical tests
551Virchows Arch (2020) 477:545–555
In our study, all separate grading components, namely
glandular differentiation, nuclear pleomorphy, and mitotic
count, inflicted a significant impact on correctly classifying
luminal molecular subtype. Although applying histological
grade and mitotic index might reliably identify LumA tumors,
Ki67-LI is needed to correctly classify LumB tumors [40]. In
our study, specificity to identify LumA tumors decreased with
increasing histological grade. These findings are in line with
previous studies reporting frequent underestimation of tumor
grade in CNB, whereas reliable grading showed significant
association with CNB size [36].
At present, no uniform cutoff levels for Ki67-LI have been
defined and discrepancies regarding thresholds and their im-
plications for clinical decisions remain [1, 2, 17–19, 41].
Regarding this problem, an expert panel was not able to stip-
ulate an ideal cutoff point for routine use [17]. Association of
Ki67-LI values between 10 and 20% with BC outcome has
been proven in a meta-analysis [42]. Inter-observer variability
was most pronounced between 10 and 30% positivity, where
clinically valid cutoff values are suggested [43]. The normal-
ization to 5-percentile values and a variable cutoff may solve
this problem, depending on the clinical purpose [32]. For the
present study, we chose a cutoff of ≥ 20 for LumB BC, as
previously validated in a clinical trial [28].
Our study revealed no statistically significant differences in
RFS and OS depending on agreement of molecular subtype
between CNB and SR, which might be explained by the lim-
ited cohort size and the low number of events.
Previous studies suggested that digital image analysis vs.
visual determination might improve molecular subtype deter-
mination by immunohistochemistry [44]; however, compara-
tive studies using digital image analysis in assessing Ki67-LI
in CNB and SR are scarce. In these smaller cohorts, the re-
ported agreement between CNB and SR was comparable with
our results, although digital image analysis slightly improved
determination [45, 46]. Notably, none of these studies inves-
tigated the impact of molecular subtype/Ki67-LI determina-
tion on patient survival.
In our study, pathological factors such as tumor grade, size,
PR, and p53 expression significantly influenced agreement of
Ki67-LI and luminal molecular subtype between CNB and
SR. These factors mirror tumor heterogeneity and can
objectivize molecular subtype determination in CNB.
More importantly, our results question the robustness of a
single CNB-driven measurement of Ki67 in luminal BC of
low (G1) or intermediate (G2) histological grade and warrant
further investigations to improve the validity of molecular
subtype determination in these cases.
Authors’ contributions Conceptualization: Kristina A. Tendl-Schulz,
Zsuzsanna Bago-Horvath
Methodology: Kristina A. Tendl-Schulz, Fabian Rössler, Zsuzsanna
Bago-Horvath
Formal analysis and investigation: Kristina A. Tendl-Schulz, Fabian
Rössler, PhilippWimmer, UlrikeM. Heber, Katja Pinker, Rupert Bartsch,
Peter Dubsky, Florian Fitzal, Fanny Carolina Eckel, Eva-Maria
Langthaler, Günther Steger, Michael Gnant, Christian F. Singer,
Thomas H. Helbich, Zsuzsanna Bago-Horvath
Statistical analyses: Martina Mittlböck, Nicolas Kozakowski, Martin
Filipits
Writing—original draft preparation: Kristina A. Tendl-Schulz, Fabian
Rössler, Zsuzsanna Bago-Horvath
Writing—review and editing: Kristina A. Tendl-Schulz, Fabian
Rössler, Philipp Wimmer, Ulrike M. Heber, Martina Mittlböck, Nicolas
Kozakowski, Katja Pinker, Rupert Bartsch, Peter Dubsky, Florian Fitzal,
Martin Filipits, Fanny Carolina Eckel, Eva-Maria Langthaler, Günther
Steger, Michael Gnant, Christian F. Singer, Thomas H. Helbich,
Zsuzsanna Bago-Horvath
Funding information Open access funding provided by Medical
University of Vienna. Katja Pinker was in part supported by the NIH/
Fig. 3 Recurrence-free (a) and overall (b) survival of patients according
to IST inCNB/SR. Correctly diagnosed cases included 177 LumA tumors
(CNB + SR) and 199 LumB tumors (CNB + SR). Within the discordant
cases, 43 LumA tumors in CNB were upgraded to LumB by SR, and in
31 LumB, tumors in CNB were downgraded to LumA by SR.
552 Virchows Arch (2020) 477:545–555
NCI Cancer Center Support Grant P30 CA008748 of Memorial Sloan
Kettering Cancer Center.
Data availability The datasets generated during and/or analyzed during
the current study are not publicly available due to legal personal data
protection issues but are available from the corresponding author on rea-
sonable request.
Compliance with ethical standards
Conflict of interest Kristina A. Tendl-Schulz: Dr. Tendl-Schulz reports
travel support from Roche and Novartis, and lecture honoraria from
Roche outside the submitted work.
Ulrike M. Heber: Dr. Heber reports travel support from Novartis,
outside the submitted work.
Katja Pinker: Dr. Pinker received payment for activities not related to
the present article including lectures including service on speakers bu-
reaus and for travel/accommodations/meeting expenses unrelated to ac-
tivities listed from the European Society of Breast Imaging (MRI educa-
tional course, annual scientific meeting).
Rupert Bartsch: Dr. Bartsch reports lecture honoraria from BMS,
Lilly, Novartis, Roche, Pfizer, and Pierre-Fabre, advisory role for MSD,
Lilly, Novartis, Roche, Pfizer, Pierre-Fabre, and Daiichi, and research
support from Novartis and Roche, outside the submitted work.
Peter Dubsky: Dr. Dubsky reports grants from Cepheid/Danaher, out-
side the submitted work.
Florian Fitzal: Dr. Fitzal reports financial support for travel, research,
and ad board: Pfizer, Astra Zeneca, MyriadMyriad, Comesa, Bondimed,
Astra Zeneca, Novartis, Roche, Springer; outside the submitted work.
Martin Filipits: Dr. Filipits reports grants and personal fees from Astra
Zeneca, personal fees from Bayer, personal fees from Boehringer
Ingelheim, personal fees from Eli Lilly, personal fees from Merck, per-
sonal fees from MSD, personal fees from Novartis, personal fees from
Ratiopharm, personal fees from Roche, and personal fees from Myriad,
outside the submitted work.
Günther Steger: Dr. Steger reports honoraria and travel support from
Roche, outside the submitted work.
Michael Gnant: Dr. Gnant has received institutional research support
from Astra Zeneca, Roche, Novartis, and Pfizer, and has received lecture
fees, honoraria for participation on advisory boards, and travel support
from Amgen, Astra Zeneca, Celgene, EliLilly, Invectys, Pfizer,
Nanostring, Novartis, and Roche. He has served as a consultant for
Astra Zeneca and Eli Lilly, and an immediate family member is employed
by Sandoz.
Thomas H. Helbich: Dr. Helbich reports educational grants and seed
grants from Hologic, Novomed, and Bard.
Christian F Singer: Dr. Singer has received institutional research sup-
port fromNovartis, Roche, Daiichi Sanyko, Astra Zeneca, and Pfizer, and
has received honoraria, lecture fees, and travel support from Astra
Zeneca, Amgen, Novartis, Roche, Pfitzer, and EliLilly.
Zsuzsanna Bago-Horvath: Dr. Bago-Horvath reports grants from
Boehringer Ingelheim, personal fees and honoraria for participation on
advisory boards fromNovartis, Biomedica, and Roche, and travel support
from Roche, outside the submitted work.
Fabian Rössler, Philipp Wimmer, Martina Mittlböck, Nicolas
Kozakowski, Fanny Carolina Eckel, Eva-Maria Langthaler: no conflicts
of interest.
Ethics approval The present study was granted approval by the Ethics
Review Board of the Medical University of Vienna (1245/2017).
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing, adap-
tation, distribution and reproduction in any medium or format, as long as
you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons licence, and indicate if changes
were made. The images or other third party material in this article are
included in the article's Creative Commons licence, unless indicated oth-
erwise in a credit line to the material. If material is not included in the
article's Creative Commons licence and your intended use is not permitted
by statutory regulation or exceeds the permitted use, you will need to
obtain permission directly from the copyright holder. To view a copy of
this licence, visit http://creativecommons.org/licenses/by/4.0/.
References
1. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B,
Senn HJ, Panel members (2011) Strategies for subtypes—dealing
with the diversity of breast cancer: highlights of the St Gallen
International Expert Consensus on the Primary Therapy of Early
Breast Cancer 2011. Ann Oncol 22:1736–1747. https://doi.org/10.
1093/annonc/mdr304
2. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart
M, Thürlimann B, SennHJ, Albain KS, André F, Bergh J, Bonnefoi
H, Bretel-Morales D, Burstein H, Cardoso F, Castiglione-Gertsch
M, Coates AS, Colleoni M, Costa A, Curigliano G, Davidson NE,
di Leo A, Ejlertsen B, Forbes JF, Gelber RD, Gnant M, Goldhirsch
A, Goodwin P, Goss PE, Harris JR, Hayes DF, Hudis CA, Ingle JN,
Jassem J, Jiang Z, Karlsson P, Loibl S, MorrowM, Namer M, Kent
Osborne C, Partridge AH, Penault-Llorca F, Perou CM, Piccart-
Gebhart MJ, Pritchard KI, Rutgers EJT, Sedlmayer F, Semiglazov
V, Shao ZM, Smith I, Thürlimann B, ToiM, Tutt A, UntchM, Viale
G, Watanabe T, Wilcken N, Winer EP, Wood WC (2013)
Personalizing the treatment of women with early breast cancer:
highlights of the St Gallen International Expert Consensus on the
Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24:
2206–2223. https://doi.org/10.1093/annonc/mdt303
3. Cuzick J, Dowsett M, Pineda S,Wale C, Salter J, Quinn E, Zabaglo
L, Mallon E, Green AR, Ellis IO, Howell A, Buzdar AU, Forbes JF
(2011) Prognostic value of a combined estrogen receptor, proges-
terone receptor, Ki-67, and human epidermal growth factor receptor
2 immunohistochemical score and comparison with the Genomic
Health recurrence score in early breast cancer. J Clin Oncol 29:
4273–4278. https://doi.org/10.1200/JCO.2010.31.2835
4. Hugh J, Hanson J, Cheang MCU, Nielsen TO, Perou CM,
Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M,
Magherini E, Mackey J, Martin M, Vogel C (2009) Breast cancer
subtypes and response to docetaxel in node-positive breast cancer:
use of an immunohistochemical definition in the BCIRG 001 trial. J
Clin Oncol 27:1168–1176. https://doi.org/10.1200/JCO.2008.18.
1024
5. Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J,
Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ,
Nielsen TO (2009) Ki67 index, HER2 status, and prognosis of
patients with luminal B breast Cancer. J Natl Cancer Inst 101:
736–750. https://doi.org/10.1093/jnci/djp082
6. von Minckwitz G, Schmitt WD, Loibl S, Muller BM, Blohmer JU,
Sinn BV, Eidtmann H, Eiermann W, Gerber B, Tesch H, Hilfrich J,
Huober J, Fehm T, Barinoff J, Rudiger T, Erbstoesser E, Fasching
PA, Karn T,Muller V, Jackisch C, Denkert C (2013) Ki67measured
after neoadjuvant chemotherapy for primary breast cancer. Clin
Cancer Res 19:4521–4531. https://doi.org/10.1158/1078-0432.
CCR-12-3628
7. Niikura N, Sakatani T, Arima N, Ohi Y, Honma N, Kanomata N,
Yoshida K, Kadoya T, Tamaki K, Kumaki N, Iwamoto T, Sugie T,
Moriya T (2016) Assessment of the Ki67 labeling index: a Japanese
553Virchows Arch (2020) 477:545–555
validation ring study. Breast Cancer 23(1):92–100. https://doi.org/
10.1007/s12282-014-0536-0
8. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees
CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge Ø,
Pergamenschikov A, Williams C, Zhu SX, Lønning PE,
Børresen-Dale AL, Brown PO, Botstein D (2000) Molecular por-
traits of human breast tumours. Nature 406:747–752. https://doi.
org/10.1038/35021093
9. Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A,
Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM,
Lønning PE, Brown PO, Børresen-Dale AL, Botstein D (2003)
Repeated observation of breast tumor subtypes in independent gene
expression data sets. Proc Natl Acad Sci 100:8418–8423. https://
doi.org/10.1073/pnas.0932692100
10. Criscitiello C, Disalvatore D, De Laurentiis M et al (2014) High Ki-
67 score is indicative of a greater benefit from adjuvant chemother-
apy when added to endocrine therapy in luminal B HER2 negative
and node-positive breast cancer. Breast 23:69–75. https://doi.org/
10.1016/j.breast.2013.11.007
11. Munzone E, Curigliano G, Colleoni M (2013) Tailoring adjuvant
treatments for the individual patient with luminal breast cancer.
Hematol Oncol Clin North Am 27:703–714. https://doi.org/10.
1016/j.hoc.2013.05.012
12. Horimoto Y, Arakawa A, Tanabe M, Sonoue H, Igari F, Senuma K,
Tokuda E, Shimizu H, Kosaka T, Saito M (2014) Ki67 expression
and the effect of neo-adjuvant chemotherapy on luminal HER2-
negative breast cancer. BMC Cancer 14:550. https://doi.org/10.
1186/1471-2407-14-550
13. Coates AS, Winer EP, Goldhirsch A, et al (2015) Tailoring
therapies—improving the management of early breast cancer: St
Gallen International Expert Consensus on the Primary Therapy of
Early Breast Cancer 2015. Ann Oncol mdv221. https://doi.org/10.
1093/annonc/mdv221
14. Plancoulaine B, Laurinaviciene A, Herlin P, Besusparis J,
Meskauskas R, Baltrusaityte I, Iqbal Y, Laurinavicius A (2015) A
methodology for comprehensive breast cancer Ki67 labeling index
with intra-tumor heterogeneity appraisal based on hexagonal tiling
of digital image analysis data. Virchows Arch Int J Pathol 467:711–
722. https://doi.org/10.1007/s00428-015-1865-x
15. Laurinavicius A, Plancoulaine B, Rasmusson A, Besusparis J,
Augulis R, Meskauskas R, Herlin P, Laurinaviciene A, Abdelhadi
Muftah AA, Miligy I, Aleskandarany M, Rakha EA, Green AR,
Ellis IO (2016) Bimodality of intratumor Ki67 expression is an
independent prognostic factor of overall survival in patients with
invasive breast carcinoma. Virchows Arch 468:493–502. https://
doi.org/10.1007/s00428-016-1907-z
16. Gándara-Cortes M, Vázquez-Boquete Á, Fernández-Rodríguez B,
Viaño P, Ínsua D, Seoane-Seoane A, Gude F, Gallego R, Fraga M,
Antúnez JR, Curiel T, Pérez-López E, García-Caballero T (2018)
Breast cancer subtype discrimination using standardized 4-IHC and
digital image analysis. Virchows Arch 472:195–203. https://doi.
org/10.1007/s00428-017-2194-z
17. Dowsett M, Nielsen TO, A’Hern R et al (2011) Assessment of Ki67
in breast cancer: recommendations from the International Ki67 in
Breast Cancer Working Group. J Natl Cancer Inst 103:1656–1664.
https://doi.org/10.1093/jnci/djr393
18. Gadzicki D, Schubert A, Fischer C, Milde S, Lehmann U,
Steinemann D, Lück HJ, Kreipe H, Schlegelberger B (2009)
Histopathological criteria and selection algorithms for BRCA1 ge-
netic testing. Cancer Genet Cytogenet 189:105–111. https://doi.
org/10.1016/j.cancergencyto.2008.11.003
19. Rody A, Karn T, Ruckhäberle E, Müller V, Gehrmann M, Solbach
C, Ahr A, Gätje R, Holtrich U, Kaufmann M (2008) Gene expres-
sion of topoisomerase II alpha (TOP2A) by microarray analysis is
highly prognostic in estrogen receptor (ER) positive breast cancer.
Breast Cancer Res Treat 113:457–466. https://doi.org/10.1007/
s10549-008-9964-x
20. Wallis M, Tardivon A, Tarvidon A et al (2007) Guidelines from the
European Society of Breast Imaging for diagnostic interventional
breast procedures. Eur Radiol 17:581–588. https://doi.org/10.1007/
s00330-006-0408-x
21. DOWNLOADS - Overview - EUREF | European Reference
Organisation for Quality Assured Breast Screening and
Diagnostic Services. http://www.euref.org/downloads.
22. downloads.pdf. In: Eur. Guidel. Qual. Assur. Breast Cancer Screen.
Diagn. PDF. http://www.euref.org/downloads?download=24:
european-guidelines-for-quality-assurance-in-breast-cancer-
screening-and-diagnosis-pdf. Accessed 5 Jul 2017
23. Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM classifi-
cation of malignant tumours, 7 edition. Wiley-Blackwell,
Chichester, West Sussex, UK ; Hoboken, NJ
24. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast
cancer. I. The value of histological grade in breast cancer: experi-
ence from a large study with long-term follow-up. Histopathology
19:403–410
25. Elston CW, Ellis IO (2002) Pathological prognostic factors in breast
cancer. I. The value of histological grade in breast cancer: experi-
ence from a large study with long-term follow-up. C.W. Elston & I.
O. Ellis. Histopathology 1991; 19; 403–410. Histopathology 41:
151–151. https://doi.org/10.1046/j.1365-2559.2002.14691.x
26. Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL,
Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M,
Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K,
Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz
JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G,
Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC,
American Society of Clinical Oncology, College of American
Pathologists (2010) American Society of Clinical Oncology/
College of American Pathologists guideline recommendations for
immunohistochemical testing of estrogen and progesterone recep-
tors in breast cancer (unabridged version). Arch Pathol Lab Med
134:e48–e72. https://doi.org/10.1043/1543-2165-134.7.e48
27. Wolff AC, HammondMEH, Hicks DG, Dowsett M,McShane LM,
Allison KH, Allred DC, Bartlett JMS, Bilous M, Fitzgibbons P,
Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF,
Spea r s PA, Vance GH, Via l e G, Hayes DF (2013)
Recommendations for human epidermal growth factor receptor 2
testing in breast cancer: American Society of Clinical Oncology/
College of American Pathologists clinical practice guideline update.
J Clin Oncol Off J Am Soc Clin Oncol 31:3997–4013. https://doi.
org/10.1200/JCO.2013.50.9984
28. Bago-Horvath Z, Rudas M, Dubsky P, Jakesz R, Singer CF,
Kemmerling R, Greil R, Jelen A, Bohm G, Jasarevic Z, Haid A,
Gruber C, Postlberger S, Filipits M, Gnant M, for the Austrian
Breast and Colorectal Cancer Study Group (2011) Adjuvant se-
quencing of tamoxifen and anastrozole is superior to tamoxifen
alone in postmenopausal women with low proliferating breast can-
cer. Clin Cancer Res 17:7828–7834. https://doi.org/10.1158/1078-
0432.CCR-11-1846
29. Romero Q, Bendahl P-O, Klintman M, Loman N, Ingvar C, Rydén
L, Rose C, Grabau D, Borgquist S (2011) Ki67 proliferation in core
biopsies versus surgical samples-a model for neo-adjuvant breast
cancer studies. BMC Cancer 11:341. https://doi.org/10.1186/1471-
2407-11-341
30. Chen X, Sun L, Mao Y, Zhu S, Wu J, Huang O, Li Y, Chen W,
Wang J, Yuan Y, Fei X, Jin X, Shen K (2013) Preoperative core
needle biopsy is accurate in determining molecular subtypes in
invasive breast cancer. BMC Cancer 13:390. https://doi.org/10.
1186/1471-2407-13-390
31. Ricci MD, Filho C, Cabral CM et al (2012) Analysis of the concor-
dance rates between core needle biopsy and surgical excision in
554 Virchows Arch (2020) 477:545–555
patients with breast cancer. Rev Assoc Médica Bras 58:532–536.
https://doi.org/10.1590/S0104-42302012000500008
32. Cserni G, Vörös A, Liepniece-Karele I, Bianchi S, Vezzosi V,
Grabau D, Sapino A, Castellano I, Regitnig P, Foschini MP,
Zolota V, Varga Z, Figueiredo P, Decker T, Focke C, Kulka J,
Kaya H, Reiner-Concin A, Amendoeira I, Callagy G, Caffrey E,
Wesseling J, Wells C (2014) Distribution pattern of the Ki67 label-
ling index in breast cancer and its implications for choosing cut-off
values. Breast 23:259–263. https://doi.org/10.1016/j.breast.2014.
02.003
33. Cassano E, Urban LABD, Pizzamiglio M, Abbate F, Maisonneuve
P, Renne G, Viale G, Bellomi M (2006) Ultrasound-guided vacu-
um-assisted core breast biopsy: experience with 406 cases. Breast
Cancer Res Treat 102:103–110. https://doi.org/10.1007/s10549-
006-9305-x
34. Di Nubila B, Cassano E, Urban LABD et al (2006) Radiological
features and pathological–biological correlations in 348 women
with breast cancer under 35 years old. Breast 15:744–753. https://
doi.org/10.1016/j.breast.2006.02.006
35. Focke CM, Decker T, van Diest PJ (2017) Reliability of the Ki67-
labelling index in core needle biopsies of luminal breast cancers is
unaffected by biopsy volume. Ann Surg Oncol 24:1251–1257.
https://doi.org/10.1245/s10434-016-5730-1
36. Focke CM, Decker T, van Diest PJ (2016) Intratumoral heteroge-
neity of Ki67 expression in early breast cancers exceeds variability
between individual tumours. Histopathology 69:849–861. https://
doi.org/10.1111/his.13007
37. Rakha EA, Ellis IO (2007) An overview of assessment of prognos-
tic and predictive factors in breast cancer needle core biopsy spec-
imens. J Clin Pathol 60:1300–1306. https://doi.org/10.1136/jcp.
2006.045377
38. Chen X, Zhu S, Fei X, Garfield DH, Wu J, Huang O, Li Y, Zhu L,
He J, Chen W, Jin X, Shen K (2015) Surgery time interval and
molecular subtype may influence Ki67 change after core needle
biopsy in breast cancer patients. BMC Cancer 15:822. https://doi.
org/10.1186/s12885-015-1853-1
39. Chung YR, Kim HJ, Kim YA, et al (2017) Diversity index as a
novel prognostic factor in breast cancer. Oncotarget 8:97114–
97126. https://doi.org/10.18632/oncotarget.21371
40. Oddó D, Pulgar D, Elgueta N, et al (2018) Can histological grade
and mitotic index replace Ki67 to determine luminal breast cancer
subtypes? Asian Pac J Cancer Prev APJCP 19:179–183. https://doi.
org/10.22034/APJCP.2018.19.1.179
41. Alfarsi L, Johnston S, Liu D-X, Rakha E, Green AR (2018) Current
issues with luminal subtype classification in terms of prediction of
benefit from endocrine therapy in early breast cancer.
Histopathology 73:545–558. https://doi.org/10.1111/his.13523
42. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P (2008)
Proliferation markers and survival in early breast cancer: a system-
atic review and meta-analysis of 85 studies in 32,825 patients.
Breast 17:323–334. https://doi.org/10.1016/j.breast.2008.02.002
43. Varga Z, Diebold J, Dommann-Scherrer C, Frick H, Kaup D, Noske
A, Obermann E, Ohlschlegel C, Padberg B, Rakozy C, Sancho
Oliver S, Schobinger-Clement S, Schreiber-Facklam H, Singer G,
Tapia C, Wagner U, Mastropasqua MG, Viale G, Lehr HA (2012)
How reliable is Ki-67 immunohistochemistry in grade 2 breast car-
cinomas? A QA study of the Swiss Working Group of Breast- and
Gynecopathologists. PLoS One 7:e37379. https://doi.org/10.1371/
journal.pone.0037379
44. Stålhammar G, Robertson S, Wedlund L, Lippert M, Rantalainen
M, Bergh J, Hartman J (2018) Digital image analysis of Ki67 in hot
spots is superior to both manual Ki67 and mitotic counts in breast
cancer. Histopathology 72:974–989. https://doi.org/10.1111/his.
13452
45. Ahn S, Lee J, Cho M-S, Park S, Sung SH (2018) Evaluation of Ki-
67 index in core needle biopsies and matched breast cancer surgical
specimens. Arch Pathol Lab Med 142:364–368. https://doi.org/10.
5858/arpa.2017-0014-OA
46. Jeong YS, Kang J, Lee J, Yoo TK, Kim SH, Lee A (2020) Analysis
of the molecular subtypes of preoperative core needle biopsy and
surgical specimens in invasive breast cancer. J Pathol Transl Med
54:87–94. https://doi.org/10.4132/jptm.2019.10.14
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
555Virchows Arch (2020) 477:545–555
